The Name Game: Will Innovators’ Latest Battlefront Kill Biosimilars?
This article was originally published in RPM Report
Executive Summary
Having lost the battle to prevent biosimilars reaching the market at all, innovators are now pushing for them to be stamped with unique international non-proprietary names. That could prove commercially fatal for copycat biologics.